EURONEXT-PAR$DBVT
DBV Technologies · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
DBV Technologies reported financial results for the second quarter of 2021 and provided recent business developments.
DBV Technologies reported a net loss of $30.7 million for the second quarter of 2021. The company continues to advance Viaskin Peanut's regulatory dossier and expects its current cash and cash equivalents to support operations until the second half of 2022.
- Submitted the protocol for the 6-month adhesion and safety study of the modified patch (STAMP) to the FDA.
- Completed a trial in healthy adult volunteers to evaluate the adhesion of five modified Viaskin Peanut patches (CHAMP).
- Initiated PREQUAL, a Phase 1 study in healthy adult volunteers to optimize the allergen sample collection methodologies and validate the assays DBV intends to use in EQUAL.
- Received from the EMA Day 180 list of outstanding issues.
Headline financials
Revenue & EPS history
DBV Technologies · Revenue · Quarterly
-€1.49M
Forward guidance
DBV expects that its current cash and cash equivalents will support its operations until the second half of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+0.3%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+11.4%
Avg return
30 days after
47%
20 / 43 earnings
Positive
+21.6%
Q4 2018
Best reaction
-29.8%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.7% | -4.3% | -83.9% | |
| Q3 2025 | -1.2% | -5.4% | -1.4% | |
| Q1 2025 | -4.4% | +4.2% | -7.3% | |
| Q4 2024 | +7.5% | +0.9% | -1.4% | |
| Q3 2024 | -2.5% | -11.3% | +380.9% | |
| Q1 2024 | +3.7% | -14.0% | -15.4% | |
| Q4 2023 | +1.2% | +1.1% | -9.6% | |
| Q3 2023 | -2.9% | -1.9% | -29.5% | |
| Q2 2023 | +1.9% | -2.5% | -3.2% | |
| Q1 2023 | +5.8% | +4.5% | +27.6% | |
| Q4 2022 | -0.7% | +4.1% | +16.6% | |
| Q3 2022 | +2.7% | +2.0% | -9.5% | |
| Q2 2022 | -5.5% | +3.5% | -21.2% | |
| Q1 2022 | -1.6% | +6.2% | +19.4% | |
| Q4 2021 | +3.1% | +0.8% | +22.3% | |
| Q3 2021 | -29.8% | -40.9% | -41.3% | |
| Q2 2021 | -4.4% | -8.1% | +7.7% | |
| Q1 2021 | -1.1% | +0.6% | +21.4% | |
| Q4 2020 | -0.4% | +2.9% | +86.2% | |
| Q3 2020 | +0.0% | -3.5% | -16.4% | |
| Q2 2020 | -3.0% | -3.5% | -16.8% | |
| Q1 2020 | -7.7% | -7.7% | +53.6% | |
| Q4 2019 | -1.2% | +3.6% | -11.7% | |
| Q3 2019 | -0.4% | +4.0% | -13.7% | |
| Q2 2019 | +5.5% | +26.5% | +17.2% | |
| Q1 2019 | -1.7% | +14.3% | +26.5% | |
| Q4 2018 | +21.6% | +34.8% | +16.3% | |
| Q3 2018 | -2.7% | -14.8% | -18.9% | |
| Q2 2018 | -1.9% | -0.1% | -8.2% | |
| Q1 2018 | -1.3% | +3.7% | -4.9% | |
| Q4 2017 | +3.5% | +7.8% | -4.7% | |
| Q3 2017 | +5.5% | -3.4% | +17.2% | |
| Q2 2017 | +1.4% | +1.3% | +25.0% | |
| Q1 2017 | -0.3% | -1.7% | +1.3% | |
| Q4 2016 | -1.1% | -0.4% | -1.0% | |
| Q3 2016 | +1.1% | +1.9% | -2.7% | |
| Q2 2016 | +3.5% | +0.6% | +6.8% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | -2.3% | — | — | |
| Q3 2015 | +3.7% | — | — | |
| Q2 2015 | +4.3% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | +5.2% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro